ATLANTA, Nov. 5, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today accepted the 2010 Southeast BIO (SEBIO) Deal of the Year: Strategic Transaction award at a ceremony held at the conclusion of the organization's 12 th Annual Investor Forum. The SEBIO Annual Investor Forum is the region's premier life sciences venture capital conference and attracts an estimated 400 attendees. Rick Eiswirth, Alimera's chief operating officer and chief financial officer, accepted the award on behalf of the company. "As one of the fastest growing industry hubs in the country, Southeast BIO is in a unique position to recognize some of the nation's leading life sciences companies," remarked Jennifer Moore, Ph.D., executive director of SEBIO. "Alimera is an outstanding example of a sustainable and innovative business, and we are delighted to honor their contributions today among industry peers and venture capital investors." Alimera was selected for this award as a result of the company's initial public offering and venture debt raise totaling more than $100 million earlier this year. On April 21, 2010, Alimera completed its initial public offering of 6.55 million shares of common stock, resulting in net proceeds to Alimera of approximately $68.4 million. Shares of Alimera common stock began trading on the NASDAQ Global Market under the symbol "ALIM" on Thursday, April 22, 2010. In October, 2010, Alimera obtained a $32.5 million senior secured credit facility to help fund its working capital requirements. "Alimera is proud to be recognized by SEBIO for our strategic financial transactions and as a driving force in the region's life sciences industry," said Eiswirth. "We hope our investors will continue to benefit from our recent progressive strides, namely the positive results from our Phase 3 (FAME™) clinical trials of our lead product candidate, Iluvien®, for patients with diabetic macular edema (DME), which is now under Priority Review by the FDA."